tiprankstipranks
Advertisement
Advertisement
Vertex Steps Into Autoimmune Care: Mid-Stage Myasthenia Gravis Trial Shows Growing Pipeline Ambition
PremiumCompany AnnouncementsVertex Steps Into Autoimmune Care: Mid-Stage Myasthenia Gravis Trial Shows Growing Pipeline Ambition
1M ago
Citizens biotechnology analyst holds analyst/industry conference call
Premium
The Fly
Citizens biotechnology analyst holds analyst/industry conference call
1M ago
Vertex Shareholders Endorse Board, Governance and Equity Plan
Premium
Company Announcements
Vertex Shareholders Endorse Board, Governance and Equity Plan
2M ago
Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
PremiumThe FlyVertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
2M ago
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
Premium
The Fly
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
2M ago
Analyst Maintains Hold on Vertex as Strong CF Franchise Offsets Mixed Q1 Results and Non‑CF Pipeline Uncertainty
Premium
Ratings
Analyst Maintains Hold on Vertex as Strong CF Franchise Offsets Mixed Q1 Results and Non‑CF Pipeline Uncertainty
2M ago
Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals
PremiumThe FlyModerna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals
2M ago
Vertex Pharmaceuticals reports Q1 EPS $4.02, consensus $4.31
Premium
The Fly
Vertex Pharmaceuticals reports Q1 EPS $4.02, consensus $4.31
2M ago
Vertex Pharmaceuticals affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B
Premium
The Fly
Vertex Pharmaceuticals affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100